Question {#ccr3749-sec-0001}
========

New targeted inhibitors of B‐cell receptor, such as ibrutinib, yield remarkable responses in patients with CLL. Does the quality of response gradually improve with duration of treatment?

Discussion {#ccr3749-sec-0002}
==========

An 83‐year‐old man with CLL refractory to rituximab and bendamustine presented a massive enlargement of mesenteric lymph nodes without histologic transformation into Richter syndrome.

Continuous oral ibrutinib 420 mg/daily was started. A transient lymphocytosis up to 85 × 10^9^/L after 1 month of therapy was considered to be treatment related [1](#ccr3749-bib-0001){ref-type="ref"}. On the other hand, sequential CT scanning demonstrated a progressive shrinkage of the abdominal lymph nodes with the best overall response obtained at 12 months (Fig. [1](#ccr3749-fig-0001){ref-type="fig"}). The concomitant minimal residual disease (MRD) negativity in the blood or bone marrow denoted complete response (International Workshop on CLL criteria) [2](#ccr3749-bib-0002){ref-type="ref"}.

![Progressive changes in abdominal lymph nodes by CT scan in a patient with CLL treated with ibrutinib. Images refer to baseline (Panel A) and to evaluation after 3 (Panel B), 6 (Panel C), 12 (Panel D), and 24 (Panel E) months of therapy.](CCR3-5-75-g001){#ccr3749-fig-0001}
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